Apixaban

Pharmacologic Category

Anticoagulant; Anticoagulant, Factor Xa Inhibitor; Direct Oral Anticoagulant (DOAC)

Dosing: Adult

Heparin-induced thrombocytopenia (off-label use): Note: For treatment of acute heparin-induced thrombocytopenia, either as initial therapy in selected hemodynamically stable patients or after initial therapy with a parenteral nonheparin anticoagulant (Kunk 2017; Shatzel 2016; Warkentin 2017).

Heparin-induced thrombocytopenia with or without thrombosis: Oral: 10 mg twice daily for 7 days or until platelet count recovery, whichever is longer, followed by 5 mg twice daily. Note: If initially treated with a parenteral nonheparin anticoagulant, can transition to 5 mg twice daily after platelet count recovery. However, if the parenteral nonheparin anticoagulant is administered for <7 days, transition to 10 mg twice daily; then after a total of 7 days with nonheparin anticoagulation, reduce to 5 mg twice daily (Coutre 2019). For patients without thrombosis, some experts start 5 mg twice daily regardless of whether parenteral anticoagulation was used initially (ASH [Cuker 2018]).

Duration: Not well established:

Heparin-induced thrombocytopenia without thrombosis: Typically, 4 weeks to 3 months (ACCP [Linkins 2012]). Some experts allow for discontinuation of anticoagulation after platelet count recovery, potentially resulting in a shorter duration (ASH [Cuker 2018]).

Heparin-induced thrombocytopenia without thrombosis with thrombosis: Typically, 3 to 6 months (ACCP [Linkins 2012]; ASH [Cuker 2018]).

Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism): Oral: 5 mg twice daily unless patient has any 2 of the following: Age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL (133 mcmol/L), then reduce dose to 2.5 mg twice daily.

Post-percutaneous coronary intervention with stent placement and nonvalvular atrial fibrillation: Oral: 5 mg twice daily unless patient has any 2 of the following: Age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL (133 mcmol/L), then reduce dose to 2.5 mg twice daily; administer with an appropriate antithrombotic regimen including clopidogrel (preferred P2Y12 inhibitor in this situation) with or without aspirin, depending on risks for thrombosis and bleeding (Lopes 2019; Sarafoff 2020).

Venous thromboembolism:

Deep vein thrombosis and/or pulmonary embolism treatment:

Note: For initial therapy, without prior treatment with a parenteral anticoagulant (in hemodynamically stable patients without extensive clot burden) or as transition from parenteral anticoagulant. May be used in patients with active cancer (eg, metastatic disease or receiving chemotherapy), but data are limited. However, in patients with gastrointestinal cancer, low molecular weight heparin (LMWH) is preferred (ASCO [Key 2020]; Bauer 2020; McBane 2019).

Oral: 10 mg twice daily for 7 days followed by 5 mg twice daily.

Duration of therapeutic anticoagulation (first episode, general recommendations): Optimal duration of therapy is unknown and is dependent on many factors, such as whether provoking events were present, patient risk factors for recurrence and bleeding, and individual preferences:

Provoked pulmonary embolism or deep vein thrombosis: 3 months (provided provoking risk factor is no longer present) (ACCP [Kearon 2016]).

Unprovoked pulmonary embolism or deep vein thrombosis (proximal or isolated distal): ≥3 months depending on risk of venous thromboembolism recurrence and bleeding (ACCP [Kearon 2016]; ACCP [Kearon 2012]; ISTH [Baglin 2012]).

Note: All patients receiving indefinite therapeutic anticoagulation with no specified stop date should be reassessed at periodic intervals.

Indefinite anticoagulation (reduced-intensity dosing for prophylaxis against venous thromboembolism recurrence): Note: For patients at elevated risk of recurrent VTE following at least 6 months of therapeutic anticoagulation. This reduced-intensity regimen is not recommended if indefinite full anticoagulation is indicated (Lip 2018): Oral: 2.5 mg twice daily (Agnelli 2013a).

Venous thromboembolism prophylaxis:

Total hip arthroplasty or total knee arthroplasty: Oral: 2.5 mg twice daily beginning 12 to 24 hours postoperatively.

Duration: Optimal duration of prophylaxis is unknown but it is usually given for a minimum of 10 to 14 days and can be extended for up to 35 days (Eikelboom 2001; ACCP [Falck-Ytter 2012]); some experts suggest a duration in the lower end of the range (10 to 14 days) for total knee arthroplasty or higher end of range (~30 days) for THA (Pai 2018).

Transitioning between anticoagulants: Note: This provides general guidance on transitioning between anticoagulants; also refer to local protocol for additional detail.

Transitioning from another anticoagulant to apixaban:

Transitioning from low-molecular-weight heparin or fondaparinux (therapeutic dose) to apixaban:

General transition recommendation: Initiate apixaban at the time of the next scheduled dose of the parenteral anticoagulant.

Venous thromboembolism initial treatment transition (alternate recommendation): For acute VTE, some experts start apixaban within 6 to 12 hours after the last dose of a twice daily LMWH regimen or within 12 to 24 hours after a once-daily regimen (Hull 2018b).

Transitioning from unfractionated heparin continuous infusion to apixaban: Start apixaban when the parenteral anticoagulant infusion is stopped (consult local protocol if the aPTT is above the target range) (Hull 2018b).

Transitioning from warfarin to apixaban: Discontinue warfarin and initiate apixaban as soon as the INR falls to <2 (US labeling).

Transitioning from apixaban to another anticoagulant:

Transitioning from apixaban to unfractionated heparin continuous infusion, low-molecular-weight heparin, or fondaparinux: Start the parenteral anticoagulant when the next dose of apixaban was scheduled to be given.

Transitioning from apixaban to warfarin: Apixaban can elevate the INR, complicating interpretation if overlapped with warfarin. To minimize interference, check INR near the end of apixaban dosing interval. Some experts suggest overlapping apixaban with warfarin for ≥2 days until INR is therapeutic. An alternative is to stop apixaban, start warfarin the same day, and bridge with a parenteral anticoagulant until the desired INR is reached (Leung 2019).

Transitioning between direct oral anticoagulants: Start the new direct oral anticoagulant (DOAC) when the next dose of the previous DOAC was scheduled to be given (Leung 2019).

Transitioning between anticoagulants in the perioperative setting: See 2017 AHA Scientific Statement, "Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting."

Dosage adjustment of apixaban with concomitant medications:

Strong dual CYP3A4 and P-glycoprotein inhibitors (eg, ketoconazole, itraconazole, ritonavir):

Recommended apixaban doses >2.5 mg twice daily: Reduce apixaban dose by 50%.

Recommended apixaban dose of 2.5 mg twice daily: Avoid concomitant use.

Strong dual CYP3A4 and P-glycoprotein inducers (eg, rifampin, carbamazepine, phenytoin, St John's wort): Avoid concomitant use.

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Refer to adult dosing. Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism): If patient is ≥80 years of age and either weighs ≤60 kg or has a serum creatinine ≥1.5 mg/dL (133 mcmol/L), then reduce dose to 2.5 mg twice daily.

Dosing: Renal Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP; Michael Heung, MD, MS.

Note: Clinical trials for the below indications excluded patients either with serum creatinine >2.5 mg/dL or CrCl <25 mL/minute (Agnelli 2013a; Agnelli 2013b; Connolly 2011; Granger 2011) or with CrCl <30 mL/minute (ADVANCE-1 [Lassen 2009]; ADVANCE-2 [Lassen 2010b]; ADVANCE-3 [Lassen 2010a]). Therefore, there is no clinical trial data on safety or efficacy in patients with advanced chronic kidney disease (CKD). Retrospective studies suggest similar efficacy and no increased bleeding risk with use of apixaban when compared to warfarin in patients with advanced CKD (CrCl <25 mL/minute) (Herndon 2019; Schafer 2018; Stanton 2017) and dialysis patients (Chokesuwattanaskul 2018; Reed 2018; Siontis 2018). However, until more robust data become available, some experts avoid use of apixaban for all indications in patients with a severe reduction in kidney function (CrCl <25 mL/minute, including dialysis) since safety and efficacy remain untested and cannot be assured (Hull 2018b; Manning 2018; Pai 2018).

Deep vein thrombosis and/or pulmonary embolism treatment; also Indefinite anticoagulation (reduced intensity dosing for prophylaxis against venous thromboembolism recurrence): No dosage adjustment is recommended by the manufacturer for any degree of reduced kidney function.

Hemodialysis, intermittent (thrice weekly): Not dialyzable to minimally dialyzable (AUC decreased by 14% over 4 hours) (Wang 2016). According to the manufacturer, no dosage adjustment necessary.

Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism):

Serum creatinine <1.5 mg/dL (133 micromol/L): No dosage adjustment necessary unless ≥80 years of age and body weight ≤60 kg, then reduce dose to 2.5 mg twice daily.

Serum creatinine ≥1.5 mg/dL (133 micromol/L) and either ≥80 years of age or body weight ≤60 kg: 2.5 mg twice daily.

Severe or end-stage renal disease (ESRD) not requiring dialysis: Apixaban or warfarin is considered appropriate (AHA/ACC/HRS [January 2014]; AHA/ACC/HRS [January 2019]). Some experts recommend apixaban 2.5 mg twice daily for CrCl 15 to 29 mL/minute (ACCP [Lip 2018]).

Hemodialysis, intermittent (thrice weekly): Not dialyzable to minimally dialyzable (AUC decreased by 14% over 4 hours) (Wang 2016). According to the manufacturer, no dosage adjustment necessary unless either ≥80 years of age or body weight ≤60 kg, then reduce to 2.5 mg twice daily. The manufacturer recommendations are derived from a single-dose pharmacokinetic and pharmacodynamic (anti-Factor Xa activity) evaluation in 8 patients (Wang 2016). A multiple-dose pharmacokinetic study demonstrated drug accumulation in ESRD patients requiring hemodialysis, with a dose of 2.5 mg twice daily producing exposures similar to those produced by a 5 mg twice-daily dose in patients with normal kidney function (Mavrakanas 2017). Despite this finding, a retrospective, propensity-matched cohort study of patients with ESRD requiring hemodialysis found that apixaban 5 mg twice daily resulted in fewer thromboembolic events and fewer major bleeding events, while apixaban 2.5 mg twice daily only resulted in fewer major bleeding events compared to warfarin (Siontis 2018).

Note: Use with caution due to limited available data. Some experts avoid anticoagulation in patients with ESRD and atrial fibrillation unless risk of thromboembolism is very high (Chang 2019; KDIGO [Herzog 2011]). In patients with ESRD and atrial fibrillation requiring dialysis, in whom a decision is made to anticoagulate, apixaban or warfarin is considered appropriate (AHA/ACC/HRS [January 2014]; AHA/ACC/HRS [January 2019]).

Total hip arthroplasty or total knee arthroplasty: No dosage adjustment is recommended by the manufacturer for any degree of reduced kidney function.

Hemodialysis, intermittent (thrice weekly): Not dialyzable to minimally dialyzable (AUC decreased by 14% over 4 hours) (Wang 2016). According to the manufacturer, no dosage adjustment necessary.

Dosing: Hepatic Impairment: Adult

Mild impairment (Child-Pugh class A): No dosage adjustment required.

Moderate impairment (Child-Pugh class B): There are no dosage adjustments provided in manufacturer's labeling; use with caution (limited clinical experience in these patients).

Severe impairment (Child-Pugh class C): Use is not recommended.

Dosing: Obesity: Adult

The International Society on Thrombosis and Haemostasis (ISTH) 2016 guideline suggests avoiding the use of apixaban (and other direct oral anticoagulants) in patients with a BMI >40 kg/m2 or weight >120 kg due to the lack of clinical data in this population. If used in a patient with a BMI >40 kg/m2 or weight >120 kg, ISTH suggests measuring peak and trough levels using an anti-factor Xa assay or mass spectrometry. If drug level is below the expected range, ISTH suggests changing to a vitamin K antagonist rather than adjusting the dose of apixaban (ISTH [Martin 2016]).

Calculations

• Modified Wells Score for DVT
• Pulmonary Embolism Wells Score

Use: Labeled Indications

Deep vein thrombosis: Treatment of deep vein thrombosis (DVT); to reduce the risk of recurrent DVT following initial therapy

Nonvalvular atrial fibrillation: To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF)

Postoperative venous thromboprophylaxis following hip or knee replacement surgery: Prophylaxis of DVT, which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery

Pulmonary embolism: Treatment of PE; to reduce the risk of recurrent PE following initial therapy

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

Heparin-induced thrombocytopenia (treatment)Level of Evidence [C, G]

Data from several case reports and retrospective studies suggest that apixaban may be used in the management of patients with heparin-induced thrombocytopenia (HIT) Ref.

Based on the American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia, apixaban is an effective and recommended agent for heparin-induced thrombocytopenia complicated by thrombosis (HITT) or heparin-induced thrombocytopenia without thrombosis (isolated HIT).

Recurrent stroke/transient ischemic attacks (prevention)Level of Evidence [G]

Based on the American Heart Association/American Stroke Association (AHA/ASA) guidelines for the prevention of stroke in patients with stroke and transient ischemic attack, apixaban may be considered as an alternative to warfarin for the prevention of recurrent stroke or transient ischemic attack in patients with an acute MI complicated by left ventricular mural thrombus formation or anterior or apical wall-motion abnormalities with a left ventricular ejection fraction <40% who are intolerant to warfarin because of nonhemorrhagic adverse events.

Level of Evidence Definitions

Level of Evidence Scale

Class and Related Monographs

Factor Xa Inhibitors

Clinical Practice Guidelines

Atrial Fibrillation:

AAN, “Prevention of Stroke in Nonvalvular Atrial Fibrillation,” February 2014

AHA/ACC/HRS, "2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation," January 2019.

AHA/ACC/HRS, "2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation," March 2014.

AHA/ASA, “Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation: A Science Advisory for Healthcare Professionals from the American Heart Association/American Stroke Association,” August 2012

“Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report," July 2018

Canadian Cardiovascular Society, "2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation," 2016

EHRA, “Updated EHRA practical guide for use of the non-VKA oral anticoagulants,” June 2016

Life-Threatening Hemorrhage:

ACC, “2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants” December 2017

AHA/ASA, “Guidelines for the Management of Spontaneous Intracerebral Hemorrhage,” July 2015

EHRA, “Updated European Heart Rhythm Association Practical Guide on the Use of Non-vitamin K Antagonist Anticoagulants in Patients with Non-valvular Atrial Fibrillation,” October 2015

NCS/SCCM, “Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage,” 2016

Stroke:

AHA/ASA, “Guidelines for Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack,” May 2014

Valvular Heart Disease:

“American Society of Hematology 2018 guidelines for management of venous thromboembolism,” December 2018

AHA/ACC, "2017 AHA/ACC Focused Update of the 2014 Guideline for the Management of Patients with Valvular Heart Disease," 2017

AHA/ACC, “2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease,” March 2014

“British Thoracic Society Guideline for the Initial Management of Pulmonary Embolism" June 2018

VTE:

ACCP, Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report,” February 2016

ASCO, “Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update,” August 2019

ASH, “American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism,” December 2018

Other:

AHA Scientific Statement, “Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting,” 2017

Administration: Oral

Administer without regard to meals. After hip/knee replacement, initial dose should be administered 12 to 24 hours postoperatively. If patient unable to swallow whole tablets, may crush 5 mg or 2.5 mg tablets and suspend in 60 mL of water, D5W, or apple juice or mix with applesauce; administer immediately. For delivery through a nasogastric tube, crushed tablets may be suspended in 60 mL of water or D5W followed by immediate delivery. Crushed tablets are stable in water, D5W, apple juice, and applesauce for up to 4 hours.

Storage/Stability

Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to treat or prevent blood clots.

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Bleeding like vomiting blood or vomit that looks like coffee grounds; coughing up blood; blood in the urine; black, red, or tarry stools; bleeding from the gums; abnormal vaginal bleeding; bruises without a reason or that get bigger; or any severe or persistent bleeding

• Severe cerebrovascular disease like change in strength on one side is greater than the other, difficulty speaking or thinking, change in balance, or vision changes

• Back pain

• Numbness or tingling feeling

• Muscle weakness

• Paralysis

• Leaking of urine

• Leaking of stool

• A fall hitting the head

• Dizziness

• Passing out

• Loss of strength and energy

• Confusion

• Headache

• Joint pain

• Chest pain

• Joint swelling

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

High alert medication:

National Patient Safety Goals:

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202155s021lbl.pdf#page=41, must be dispensed with this medication.

Contraindications

US labeling: Severe hypersensitivity reaction (ie, anaphylaxis) to apixaban or any component of the formulation; active pathological bleeding

Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to apixaban or any component of the formulation; lesions or conditions at increased risk of clinically significant bleeding (eg, cerebral infarct [ischemic or hemorrhagic], active peptic ulcer disease with recent bleeding; patients with spontaneous or acquired impairment of hemostasis); hepatic disease associated with coagulopathy and clinically relevant bleeding risk; concomitant systemic treatment with agents that are strong inhibitors of both CYP3A4 and P-glycoprotein (P-gp); concomitant treatment with any other anticoagulant including unfractionated heparin (except at doses used to maintain patency of central venous or arterial catheter), low molecular weight heparins, heparin derivatives (eg, fondaparinux), and oral anticoagulants including warfarin, dabigatran, rivaroxaban except when transitioning to or from apixaban therapy

Warnings/Precautions

Concerns related to adverse effects:

• Bleeding: May increase the risk of bleeding, including severe and potentially fatal bleeding. Concomitant use of drugs that affect hemostasis increases the risk of bleeding. Discontinue therapy with active pathological hemorrhage and promptly evaluate for bleeding source. Andexanet alfa is available for reversal of apixaban in patients experiencing life-threatening or uncontrolled bleeding. Apixaban is highly protein-bound; therefore, hemodialysis is ineffective. Depending on the bleeding severity, activated oral charcoal should be considered if ingestion occurred within 1 to 2 hours of presentation. The following alternative options may also be considered depending specific clinical scenario: 4-factor unactivated prothrombin concentrate (PCC) (eg, Kcentra) or 4-factor activated prothrombin complex concentrate (aPCC) (eg, FEIBA). Some studies and case reports have shown moderate success in correcting coagulation tests with some of these agents; however, correction of coagulation tests does not imply reversal of the anticoagulation effect of the medication (AHA/ASA [Hemphill 2015; EHRA [Heidbuchel 2015]; NCS/SCCM [Frontera 2016]).

• Thromboembolic events: [US Boxed Warning]: Premature discontinuation of any oral anticoagulant, including apixaban, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. When used to prevent stroke in patients with nonvalvular atrial fibrillation, an increased risk of stroke was observed upon transition from apixaban to warfarin in clinical trials. If apixaban must be discontinued for reasons other than bleeding or completion of a course of therapy, consider the use of another anticoagulant. In patients with non-valvular atrial fibrillation who had an acute ischemic stroke while receiving a direct oral anticoagulant (DOAC) (eg, apixaban), guidelines generally support withholding oral anticoagulation until 1 to 2 weeks after the ischemic stroke (time frame may vary with shorter times for transient ischemic attack or small, non-disabling stroke and longer times for moderate-to-severe stroke) (AHA/ASA [Kernan 2014]).

Disease-related concerns:

• Antiphospholipid syndrome: Use not recommended for patients with a history of thrombosis who are diagnosed with antiphospholipid syndrome; safety and efficacy have not been established. Patients positive for all three antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I) may have increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.

• Bariatric surgery:

– Altered absorption: Evaluate the risk versus benefit of possible decreased drug absorption against the consideration of alternative anticoagulants; efficacy may be decreased after gastric bypass or sleeve gastrectomy. Apixaban’s absorption appears to occur primarily in the small intestine. Peak apixaban concentrations and total AUC are reduced by 60% when released in the distal small intestine and further reduced to 90% and 84%, respectively, when released in the ascending colon (Frost 2013).

– Rivaroxaban: Peak concentrations and AUC were reduced by 56% and 29%, respectively, when released into the proximal small intestine and further reduced in the distal small intestine or colon (manufacturer labeling 2019). Patients with significantly altered GI tracts are represented by small series and case reports (Hakeam 2017). The available data are conflicting for absorption alterations, derived from small populations, and underrepresent individual direct oral anticoagulants and surgeries (Kroll 2017; Kroll 2018; Lee 2013; Rottenstreich 2018).

• Hepatic impairment: Use with caution in moderate impairment (Child-Pugh class B) as there is limited clinical experience in these patients; dosing recommendations cannot be provided. Use in severe hepatic impairment (Child-Pugh class C) is not recommended.

• Renal impairment: Systemic exposure increases with worsening renal function. Bleeding risk may be increased in severe renal impairment (CrCl <15 to 29 mL/minute); use with caution. Patients with significant renal impairment (eg, CrCl <30 mL/minute) were excluded from clinical trials. Dosage reduction is recommended for patients with nonvalvular atrial fibrillation and 2 of the 3 following risk factors: Serum creatinine ≥1.5 mg/dL (133 mcmol/L), age ≥80 years, or weight ≤60 kg. Compared to warfarin, apixaban has been shown to be associated with less major bleeding among all ranges of estimated GFRs as determined by initial serum creatinine; however, patients with a serum creatinine >2.5 mg/dL (221 mcmol/L) or CrCl <25 mL/minute (as determined by Cockcroft-Gault equation) were excluded from the analysis (Hohnloser 2012). Use with caution in patients on hemodialysis; limited information is available. In patients who develop acute kidney injury during use, closely monitor or consider switching to an alternative anticoagulant due to an increased risk of bleeding in this population (AHA [Raval 2017]).

• Valvular disease: Use is not recommended in patients with prosthetic heart valves or significant rheumatic heart disease. Avoid use of DOACs in patients with mechanical valves or with moderate to severe mitral stenosis. However, a DOAC may be used in patients with atrial fibrillation and native aortic valve disease, tricuspid valve disease, or mitral regurgitation when anticoagulation is required (AHA/ACC/HRS [January 2014, 2019]; AHA/ACC [Nishimura 2017]).

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Special populations:

• Acutely ill medical patients: In acutely ill patients (eg, heart failure, respiratory failure) at risk for venous thromboembolism (VTE) receiving apixaban for extended VTE prophylaxis, an increased incidence of major bleeding without greater efficacy was observed with extended apixaban therapy (eg, 30 days) versus low molecular weight heparin (enoxaparin) therapy for 1 to 2 weeks (Goldhaber 2011).

• Elderly: Systemic exposure is increased ~32% in patients >65 years of age; however, dose reductions are not required. Dosage reduction is recommended for patients with nonvalvular atrial fibrillation who are ≥80 years of age and either weigh ≤60 kg or with a serum creatinine ≥1.5 mg/dL (133 mcmol/L).

Other warnings/precautions:

• Appropriate use: In hemodynamically unstable patients with acute PE or patients with PE requiring thrombolysis or pulmonary embolectomy, the use of apixaban is not recommended as an alternative to unfractionated heparin for initial treatment.

• Body weight: Systemic exposure may be increased by 20% to 30% in patients <50 kg and decreased by 20% to 30% in patients >120 kg; dosage reduction is recommended for patients with nonvalvular atrial fibrillation weighing ≤60 kg and either ≥80 years of age or with a serum creatinine ≥1.5 mg/dL (133 mcmol/L).

• Spinal or epidural hematoma: [US Boxed Warning]: Spinal or epidural hematomas resulting in long-term or permanent paralysis may occur with neuraxial anesthesia (epidural or spinal anesthesia) or spinal/epidural puncture; the risk is increased by the use of indwelling epidural catheters with concomitant administration of other drugs that affect hemostasis (eg, NSAIDS, platelet inhibitors, other anticoagulants), in patients with a history of traumatic or repeated epidural or spinal punctures, a history of spinal deformity or surgery, or if optimal timing between the administration of apixaban and neuraxial procedures is not known. Consider the potential benefit versus risk prior to neuraxial intervention in patients who are anticoagulated or scheduled to be anticoagulated for thromboprophylaxis. In patients who receive both apixaban and neuraxial anesthesia, avoid removal of epidural or intrathecal catheter for at least 24 hours following last apixaban dose; avoid apixaban administration for at least 5 hours following catheter removal. If traumatic puncture occurs, delay administration of apixaban for at least 48 hours. Monitor frequently for signs of neurologic impairment (eg, numbness/weakness of legs, bowel/bladder dysfunction). If neurologic impairment is noted, prompt treatment is necessary.

* See Cautions in AHFS Essentials for additional information.

Geriatric Considerations

The median age of subjects in the ARISTOTLE study (apixaban versus warfarin patients with atrial fibrillation) was 70 years and 31% of subjects were 75 years and older. Age did not affect the incidence of major bleeding or efficacy outcomes (Granger, 2011). According to the manufacturer more than 50% of subjects in the ADVANCE-1 (knee), -2 (knee), and -3 (hip) DVT prevention post joint replacement trials were ≥65 years, and 16% were ≥75 years. The mean ages in these trials were ~61, ~66, and ~61 years, respectively. No differences in efficacy or safety were identified between younger and older subjects.

Reproductive Considerations

Information related to the use of direct acting oral anticoagulants in pregnancy is limited; until safety data are available, adequate contraception is recommended during therapy for females of childbearing potential. Females planning a pregnancy should be switched to alternative anticoagulants prior to conception (Cohen 2016).

Pregnancy Considerations

Based on placenta perfusion studies, apixaban is expected to cross the placenta (Bapat 2016).

Information specific to the use of apixaban in pregnancy is limited (Beyer-Westendorf 2016; Königsbrügge 2014; Lameijer 2018). Use of direct acting oral anticoagulants increases the risk of bleeding in all patients. When used in pregnancy, there is also the potential for fetal bleeding or subclinical placental bleeding which may increase the risk of miscarriage, preterm delivery, fetal compromise, or stillbirth (Cohen 2016).

Data are insufficient to evaluate the safety of direct acting oral anticoagulants during pregnancy (Bates 2012) and use in pregnant females is not recommended (Regitz-Zagrosek [ESC 2018]). Agents other than apixaban are preferred for the treatment of AF, PE, or VTE in pregnant patients (Howard 2018; Kearon 2016; Lip 2018; Regitz-Zagrosek [ESC 2018]). Patients should be switched to an alternative anticoagulant if pregnancy occurs during therapy. Fetal monitoring that includes evaluations for fetal bleeding and assessments for risk of preterm delivery are recommended if the direct acting oral anticoagulant is continued (Cohen 2016).

Breast-Feeding Considerations

It is not known if apixaban is present in breast milk.

Until safety data are available, direct acting oral anticoagulants are not recommended for use in patients who are breastfeeding; use of an alternative anticoagulant is preferred (Bates 2012; Cohen 2016).

Briggs' Drugs in Pregnancy & Lactation

• Apixaban

Adverse Reactions

>10%: Hematologic & oncologic: Hemorrhage (≤15%; major: ≤2%; clinically relevant nonmajor bleeding: 4%)

1% to 10%:

Endocrine & metabolic: Heavy menstrual bleeding (1%)

Gastrointestinal: Nausea (3%), gingival hemorrhage (≤1%)

Genitourinary: Hematuria (≤2%)

Hematologic & oncologic: Anemia (3%), bruise (1% to 2%), hematoma (1% to 2%), rectal hemorrhage (≤1%)

Respiratory: Epistaxis (≤4%), hemoptysis (≤1%)

<1%: Abnormal uterine bleeding, acute posthemorrhagic anemia, allergic angioedema, anal hemorrhage, anaphylaxis, conjunctival hemorrhage, dermal hemorrhage, gastrointestinal hemorrhage, genital bleeding, hematemesis, hematochezia, hematoma at injection site, hemophthalmos, hemorrhoidal bleeding, hypersensitivity reaction, hypotension, incision site hemorrhage, increased gamma-glutamyl transferase, increased serum alkaline phosphatase, increased serum bilirubin, increased serum transaminases, intracranial hemorrhage, melena, muscle hemorrhage, perioperative blood loss, periorbital hematoma, petechia, postoperative hematoma (incision site), postprocedural hemorrhage, puncture site bleeding, retinal hemorrhage, skin rash, syncope, thrombocytopenia, wound hemorrhage, wound secretion

Frequency not defined:

Cardiovascular: Thrombosis (with premature discontinuation)

Central nervous system: Epidural intracranial hemorrhage (in patients receiving neuraxial anesthesia or undergoing spinal puncture)

Hematologic & oncologic: Spinal hematoma (in patients receiving neuraxial anesthesia or undergoing spinal puncture)

Postmarketing: Periorbital edema (Ahmad 2018)

* See Cautions in AHFS Essentials for additional information.

Toxicology

• Factor Xa Inhibitors, Oral

Metabolism/Transport Effects

Substrate of BCRP/ABCG2, CYP1A2 (minor), CYP2C19 (minor), CYP2C8 (minor), CYP2C9 (minor), CYP3A4 (major), P-glycoprotein/ABCB1; Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions Open Interactions

Acalabrutinib: May enhance the anticoagulant effect of Anticoagulants. Risk C: Monitor therapy

Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely. Risk C: Monitor therapy

Anticoagulants: Apixaban may enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Exceptions: Acenocoumarol; Warfarin. Risk X: Avoid combination

Antiplatelet Agents (P2Y12 Inhibitors): May enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor. Risk D: Consider therapy modification

Aspirin: May enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely. Risk D: Consider therapy modification

Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Bromperidol: May enhance the adverse/toxic effect of Anticoagulants. Risk C: Monitor therapy

Caplacizumab: May enhance the anticoagulant effect of Anticoagulants. Risk C: Monitor therapy

Clarithromycin: May increase the serum concentration of Apixaban. Risk C: Monitor therapy

Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. Risk C: Monitor therapy

CYP3A4 Inducers (Strong): May decrease the serum concentration of Apixaban. Management: Avoid concurrent use of apixaban with strong CYP3A4 inducers whenever possible. Use of a strong CYP3A4 inducer with apixaban should be strictly avoided in any patient who is using an agent (either the CYP3A4 inducer or a third drug) that induces P-gp. Exceptions: Apalutamide; CarBAMazepine; Fosphenytoin; Phenytoin; RifAMPin. Risk D: Consider therapy modification

CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Apixaban. Risk C: Monitor therapy

CYP3A4 Inhibitors (Strong): May increase the serum concentration of Apixaban. Risk C: Monitor therapy

Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Risk X: Avoid combination

Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible. If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects). Risk D: Consider therapy modification

Dasatinib: May enhance the anticoagulant effect of Anticoagulants. Risk C: Monitor therapy

Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Risk C: Monitor therapy

Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. Risk C: Monitor therapy

Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another. See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment. Risk X: Avoid combination

Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring. Risk D: Consider therapy modification

Erdafitinib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Estrogen Derivatives: May diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of estrogens against the potential increased risk of procoagulant effects and thromboembolism. Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations. Exceptions: Tibolone. Risk D: Consider therapy modification

Factor X (Human): Anticoagulants (Inhibitors of Factor Xa) may diminish the therapeutic effect of Factor X (Human). Risk C: Monitor therapy

Fat Emulsion (Fish Oil Based): May enhance the anticoagulant effect of Anticoagulants. Risk C: Monitor therapy

Fusidic Acid (Systemic): May increase the serum concentration of Apixaban. Management: Consider alternatives to this combination when possible. Apixaban dose adjustments may be required when used with systemic fusidic acid. Patients using this combination should be monitored extra closely. Risk D: Consider therapy modification

Hemin: May enhance the anticoagulant effect of Anticoagulants. Risk X: Avoid combination

Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur. Management: Avoid such combinations when possible. If used concomitantly, increase diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds). Risk D: Consider therapy modification

Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. Risk C: Monitor therapy

Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants. Risk C: Monitor therapy

Inducers of CYP3A4 (Strong) and P-glycoprotein: May decrease the serum concentration of Apixaban. Risk X: Avoid combination

Inhibitors of CYP3A4 (Strong) and P-glycoprotein: May increase the serum concentration of Apixaban. Management: US labeling recommends a 50% apixaban dose reduction in patients who would otherwise receive 5 or 10 mg twice daily, and avoiding in patients who would otherwise receive 2.5 mg twice daily. Canadian labeling lists any combined use as contraindicated. Risk D: Consider therapy modification

Inotersen: May enhance the anticoagulant effect of Anticoagulants. Risk C: Monitor therapy

Ivosidenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased. Risk C: Monitor therapy

Mesoglycan: May enhance the anticoagulant effect of Anticoagulants. Risk C: Monitor therapy

MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased. Risk X: Avoid combination

Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane. Risk D: Consider therapy modification

Naproxen: May enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. Naproxen may increase the serum concentration of Apixaban. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and naproxen. If combined, monitor patients extra closely for signs and symptoms of bleeding. Risk D: Consider therapy modification

Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. Risk C: Monitor therapy

Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the anticoagulant effect of Anticoagulants. Risk C: Monitor therapy

Nonsteroidal Anti-Inflammatory Agents (Nonselective): May enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding. Risk D: Consider therapy modification

Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. Risk C: Monitor therapy

Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL. Risk X: Avoid combination

Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants. Risk C: Monitor therapy

Oritavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, oritavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses. Risk C: Monitor therapy

Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants. Risk C: Monitor therapy

Progestins: May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism. Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations. Risk D: Consider therapy modification

Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination. Risk C: Monitor therapy

Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Risk X: Avoid combination

Salicylates: May enhance the anticoagulant effect of Anticoagulants. Risk C: Monitor therapy

Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

St John's Wort: May decrease the serum concentration of Apixaban. Risk X: Avoid combination

Sugammadex: May enhance the anticoagulant effect of Anticoagulants. Risk C: Monitor therapy

Sulodexide: May enhance the anticoagulant effect of Anticoagulants. Risk C: Monitor therapy

Telavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses. Risk C: Monitor therapy

Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants. Risk C: Monitor therapy

Tibolone: May enhance the anticoagulant effect of Anticoagulants. Risk C: Monitor therapy

Tipranavir: May enhance the anticoagulant effect of Anticoagulants. Risk C: Monitor therapy

Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Urokinase: May enhance the anticoagulant effect of Anticoagulants. Risk X: Avoid combination

Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants. Risk C: Monitor therapy

Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding. Risk X: Avoid combination

Zanubrutinib: May enhance the adverse/toxic effect of Anticoagulants. Risk C: Monitor therapy

Food Interactions

Grapefruit juice may increase levels/effects of apixaban. Management: Advise patients who consume grapefruit juice during therapy to use caution; monitor for increased effects (eg, bleeding).

Genes of Interest

• Cytochrome P450 3A4
• P-Glycoprotein

Monitoring Parameters

CBC, aPTT, PT, serum creatinine, and liver function tests prior to initiation, when clinically indicated, and at least annually (AHA/ACC/HRS [January 2014]; Leung 2019)

Routine coagulation testing is not required or necessary for direct oral anticoagulants (DOACs). There are currently no FDA-approved assays or calibration reagents available.

In clinical situations when assessment of the anticoagulant effect is useful (eg, acute care, periprocedural settings, absorption), evaluating a recent creatinine clearance and time since the last dose was ingested is usually sufficient for guiding clinical decisions. No commonly used coagulation tests can definitively exclude the presence of clinically relevant serum concentrations. A prolonged PT suggests clinically relevant serum concentrations are present, but normal PT and aPTT values cannot rule out the presence of apixaban.

If available, the preferred test to rule out clinically significant serum concentrations and quantify anticoagulant effect is antifactor Xa activity calibrated specifically for apixaban (undetectable anti-Xa activity likely excludes clinically relevant drug concentrations). An antifactor Xa assay calibrated for low molecular weight heparin can rule out clinically relevant drug concentrations, but is not useful for quantification (ACC [Tomaselli 2017]; AHA [Raval 2017]; Leung 2019).

When converting from apixaban to a vitamin K antagonist (VKA), it has been recommended to perform INR testing just prior to each dose of apixaban beginning on day 3 of concurrent therapy with the VKA (Eliquis Canadian product monograph).

Reference Range

The International Council for Standardization in Haematology (ICSH) provides examples of apixaban drug levels for the 5 mg twice-daily dose, with an expected median peak of ~132 to 171 ng/mL (5th to 95th percentile of 59 to 321 ng/mL) and an expected median trough of ~63 to 103 ng/mL (5th to 95th percentile, 22 to 230 ng/mL) (Gosselin 2018). These values are intended to be used as guides to provide evidence of drug absorption, not as therapeutic targets (Leung 2019).

Advanced Practitioners Physical Assessment/Monitoring

Obtain renal function tests, CBC, and liver function tests as clinically indicated and at least annually. Consider patients age and weight as dose reduction or alternative therapy may be needed. Consider using an antifactor Xa assay or mass spectrometry to help guide treatment. Assess other medicines patient may be taking, alternate therapy or dosage adjustments may be needed. Assess for signs and symptoms of bleeding and neurological impairment. Evaluate risks vs benefits of continuing/discontinuing therapy in patients who may require neuraxial anesthesia, indwelling epidural catheter, or spinal tap. Screen for valvular disease. Allow sufficient time between discontinuation/restarting of medication and beginning/finishing neuraxial anesthesia, spinal tap and cesarean section, and/or delivery. Instruct patients that premature discontinuation of medication increases the risk of thrombotic events. Andexanet alfa is available as a reversal agent.

Nursing Physical Assessment/Monitoring

Check ordered labs and report any abnormalities. Monitor for signs and symptoms of bleeding (bruising or bleeding that is not normal, changes in menstrual periods like lots of bleeding, spotting, or bleeding between cycles, nosebleeds that won’t stop, bowel movements that are red or black like tar, throwing up blood or liquid that looks like coffee grounds). Educate patients on bleeding precautions including avoiding invasive procedures, activities that could cause injuries, and how to handle bleeding emergencies. Educate patients that grapefruit juice may increase the effects of the medication. Instruct patients not to discontinue medication prematurely. Advise patients to tell all doctors and dentists about use of an anticoagulant.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Eliquis: 2.5 mg, 5 mg

Eliquis DVT/PE Starter Pack: 5 mg

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Eliquis: 2.5 mg, 5 mg

Anatomic Therapeutic Chemical (ATC) Classification

• B01AF02

Generic Available (US)

No

Pricing: US

Tablets (Eliquis DVT/PE Starter Pack Oral)

5 mg (per each): $9.42

Tablets (Eliquis Oral)

2.5 mg (per each): $9.42

5 mg (per each): $9.42

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Inhibits platelet activation and fibrin clot formation via direct, selective and reversible inhibition of free and clot-bound factor Xa (FXa). FXa, as part of the prothrombinase complex consisting also of factor Va, calcium ions, and phospholipid, catalyzes the conversion of prothrombin to thrombin. Thrombin both activates platelets and catalyzes the conversion of fibrinogen to fibrin.

Pharmacodynamics/Kinetics

Onset: 3 to 4 hours

Distribution: Vss: ~21 L

Protein binding: ~87%

Metabolism: Hepatic predominantly via CYP3A4/5 and to a lesser extent via CYP1A2, 2C8, 2C9, 2C19, and 2J2 to inactive metabolites; O-demethylation and hydroxylation are the major sites of transformation; substrate of P-glycoprotein (P-gp) and breast cancer resistant protein (BCRP)

Bioavailability: ~50%

Half-life elimination: ~12 hours (8 to 15 hours) (AHA [Raval 2017])

Time to peak: 3 to 4 hours

Excretion: Urine (~27% as parent drug); feces (biliary and direct intestinal excretion)

Pharmacodynamics/Kinetics: Additional Considerations

Renal function impairment: In subjects with ESRD, the AUC of apixaban was 17% greater compared to those with normal renal function.

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Dental Health Professional Considerations

At this time there are no coagulation parameters for apixaban to predict the extent of bleeding. Increased bleeding may occur during invasive dental procedures in patients taking apixaban. Medical consult is suggested prior to dental invasive procedures. Routine coagulation testing (INR) is not required, or necessary, for Direct-Acting Oral Anticoagulants (DOAC).

Effects on Dental Treatment

Key adverse event(s) related to dental treatment: Surgical site bleeding may occur. See Effects on Bleeding.

Effects on Bleeding

Apixaban inhibits platelet activation and fibrin clot formation via direct, selective, and reversible inhibition of factor Xa. As with all anticoagulants, bleeding is the major adverse effect of apixaban. Hemorrhage may occur at virtually any site; risk is dependent on multiple variables including the intensity of anticoagulation and patient susceptibility. Medical consult is suggested.

Related Information

• Beers Criteria 2019: Potentially Inappropriate Medication Use in Older Adults ≥65 Years of Age
• Oral Anticoagulant Comparison Chart
• Reversal of Oral Anticoagulants

Index Terms

Non-Vitamin K Antagonist Oral Anticoagulant (NOAC) (error-prone acronym)

FDA Approval Date

December 28, 2012

References

2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674-694. doi: 10.1111/jgs.15767.[PubMed 30693946]

Agnelli G, Buller HR, Cohen A, et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013a;368(8):699-708. doi: 10.1056/NEJMoa1207541.[PubMed 23216615]

Agnelli G, Buller HR, Cohen A, et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013b;369(9):799-808.[PubMed 23808982]

Ahmad A, Steinhilber S. Periorbital edema from apixaban treatment. J Gen Intern Med. 2018;33(2):232.[PubMed 28913641]

Baglin T, Bauer K, Douketis J, Buller H, Srivastava A, Johnson G; SSC of the ISTH. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH. J Thromb Haemost. 2012;10(4):698-702. doi: 10.1111/j.1538-7836.2012.04662.x.[PubMed 22332937]

Bapat P, Pinto LS, Lubetsky A, et al. Examining the transplacental passage of apixaban using the dually perfused human placenta. J Thromb Haemost. 2016;14(7):1436-1441.[PubMed 27149680]

Bates SM, Greer IA, Middeldorp S, et al. “VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” Chest, 2012, 141(2 Suppl):e691-736.[PubMed 22315276]

Bauer KA. Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 6, 2020.[PubMed 22315276]

Beyer-Westendorf J, Michalski F, Tittl L, et al. Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. Thromb Haemost. 2016;116(4):651-658.[PubMed 27384740]

Chang SH, Wu CV, Yeh YH, et al. Efficacy and safety of oral anticoagulants in patients with atrial fibrillation and stages 4 or 5 chronic kidney disease. Am J Med. 2019;132(11):1335–1343.e6. doi:10.1016/j.amjmed.2019.06.006.[PubMed 31278930]

Chokesuwattanaskul R, Thongprayoon C, Tanawuttiwat T, Kaewput W, Pachariyanon P, Cheungpasitporn W. Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: meta-analysis [published correction appears in Pacing Clin Electrophysiol. 2018;41(7):879]. Pacing Clin Electrophysiol. 2018;41(6):627–634. doi:10.1111/pace.13331.[PubMed 27384740]

Cohen H, Arachchillage DR, Middeldorp S, Beyer-Westendorf J, Abdul-Kadir R. Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(8):1673-1676.[PubMed 27346676]

Connolly SJ, Eikelboom J, Joyner C, et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817.[PubMed 21309657]

Coutre S, Crowther M. Management of heparin-induced thrombocytopenia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 13, 2018.

Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360-3392. doi: 10.1182/bloodadvances.2018024489.[PubMed 30482768]

Davis KA, Davis DO. Direct acting oral anticoagulants for the treatment of suspected heparin-induced thrombocytopenia. Eur J Haematol. 2017;99(4):332-335. doi: 10.1111/ejh.12921.[PubMed 28672052]

Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet. 2001;358(9275):9-15. doi: 10.1016/S0140-6736(00)05249-1.[PubMed 11454370]

Eliquis (apixaban) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; June 2019.

Eliquis (apixaban) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada Co; October 2019.

Ezekwudo DE, Chacko R, Gbadamosi B, et al. Apixaban for treatment of confirmed heparin-induced thrombocytopenia: a case report and review of literature. Exp Hematol Oncol. 2017;6:21. doi: 10.1186/s40164-017-0080-7.[PubMed 28725494]

Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(suppl):e278S-e325S. doi: 10.1378/chest.11-2404.[PubMed 22315265]

Fanikos J, Burnett AE, Mahan CE, Dobesh PP. Renal function considerations for stroke prevention in atrial fibrillation. Am J Med. 2017;130(9):1015-1023. doi: 10.1016/j.amjmed.2017.04.015.[PubMed 28502818]

Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016;24(1):6-46. doi: 10.1007/s12028-015-0222-x.[PubMed 26714677]

Frost C, et al. Assessment of the sites of gastrointestinal absorption of apixaban in healthy subjects. Clin Pharmacol Drug Dev. 2013;2(1):19.

Goldhaber SZ, Leizorovicz A, Kakkar AK, et al, “Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients,” N Engl J Med, 2011, 365(23):2167-77.[PubMed 22077144]

Gosselin RC, Adcock DM, Bates SM, et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost. 2018;118(3):437-450. doi: 10.1055/s-0038-1627480.[PubMed 29433148]

Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.[PubMed 21870978]

Hakeam HA, Al-Sanea N. Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs). J Thromb Thrombolysis. 2017;43(3):343-351. doi: 10.1007/s11239-016-1465-x.[PubMed 28050755]

Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467-1507. doi: 10.1093/europace/euv309.[PubMed 26324838]

Hemphill JC 3rd, Greenberg SM, Anderson CS, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46(7):2032-2060. doi: 10.1161/STR.0000000000000069.[PubMed 26022637]

Herndon K, Guidry TJ, Wassell K, Elliott W. Characterizing the safety profile of apixaban versus warfarin in moderate to severe chronic kidney disease at a veterans affairs hospital [published online December 24, 2019]. Ann Pharmacother. 2019;1060028019897053. doi:10.1177/1060028019897053.[PubMed 31872779]

Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(6):572-586. doi: 10.1038/ki.2011.223.[PubMed 21750584]

Hohnloser SH, Hijazi Z, Thomas L, et al, “Efficacy of Apixaban When Compared With Warfarin in Relation to Renal Function in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial,” Eur Heart J, 2012, 33(22):2821-30.[PubMed 22933567]

Howard LSGE, Barden S, Condliffe R, et al. British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE). Thorax. 2018;73(Suppl 2):ii1-ii29.[PubMed 29898978]

Hull RD, Lip G. Overview of the treatment of lower extremity deep vein thrombosis (DVT). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 18, 2018a.

Hull RD, Lip G. Venous thromboembolism: Anticoagulation after initial management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 13, 2018b.

January CT, Wann LS, Alpert JS, et al; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. Circulation. doi:10.1161/CIR.0000000000000041.[PubMed 24682347]

January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circulation. 2019:CIR0000000000000665. doi: 10.1161/CIR.0000000000000665.[PubMed 30686041]

January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. Heart Rhythm. 2019. pii: S1547-5271(19)30037-2. doi: 10.1016/j.hrthm.2019.01.024.[PubMed 30703530]

Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in Chest. 2012;142(6):1698-1704]. Chest. 2012;141(2)(suppl):e419S-e496S. doi: 10.1378/chest.11-2301.[PubMed 22315268]

Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.[PubMed 26867832]

Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in Stroke. 2015;46(2):e54]. Stroke. 2014;45(7):2160-2236. doi: 10.1161/STR.0000000000000024.[PubMed 24788967]

Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496-520.[PubMed 31381464]

Khalid S, Daw H. The role of apixaban in the treatment of heparin-induced thrombocytopenia. Cureus. 2017;9(7):e1428. doi: 10.7759/cureus.1428.[PubMed 28884054]

Königsbrügge O, Langer M, Hayde M, Ay C, Pabinger I. Oral anticoagulation with rivaroxaban during pregnancy: a case report. Thromb Haemost. 2014;112(6):1323-1324.[PubMed 25055834]

Kröll D, Stirnimann G, Vogt A, et al. Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery. Br J Clin Pharmacol. 2017;83(7):1466-1475. doi: 10.1111/bcp.13243.[PubMed 28121368]

Kröll D, Nett PC, Borbély YM, et al. The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study. Surg Obes Relat Dis. 2018;14(12):1890-1896. doi: 10.1016/j.soard.2018.08.025.[PubMed 30396779]

Kunk PR, Brown J, McShane M, et al. Direct oral anticoagulants in hypercoagulable states. J Thromb Thrombolysis. 2017;43(1):79-85. doi: 10.1007/s11239-016-1420-x.[PubMed 27632140]

Lameijer H, Aalberts JJJ, van Veldhuisen DJ, Meijer K, Pieper PG. Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review. Thromb Res. 2018;169:123-127.[PubMed 30036784]

Lanau N, Mareque J, Giner L, Zabalza M. Direct oral anticoagulants and its implications in dentistry. A review of literature. J Clin Exp Dent. 2017:9(11):e1346-e1354.[PubMed 29302288]

Lassen MR, Gallus A, Raskob GE, Pineo G, Cen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010a;363(26):2487-2498.[PubMed 21175312]

Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010b;375(9717):807-815.[PubMed 20206776]

Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement [published correction appears in N Engl J Med. 2009;361(18):1814]. N Engl J Med. 2009;361(6):594-604.[PubMed 19657123]

Lee D, DeFilipp Z, Judson K, Kennedy M. Subtherapeutic anticoagulation with dabigatran following Roux-en-Y gastric bypass surgery. J Cardiol Cases. 2013;8(1):e49-e50. doi: 10.1016/j.jccase.2013.03.013.[PubMed 30546740]

Leung LLK. Direct oral anticoagulants and parenteral direct thrombin inhibitors: Dosing and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 26, 2019.

Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e495S-e530S. doi: 10.1378/chest.11-2303. Review. Erratum in: Chest. 2015;148(6):1529.[PubMed 22315270]

Lip G, Hull RD. Rationale and indications for indefinite anticoagulation in patients with venous thromboembolism. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 6, 2018.

Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST Guideline and Expert Panel Report. Chest. 2018;154(5):1121-1201. doi: 10.1016/j.chest.2018.07.040.[PubMed 30144419]

Lopes RD, Heizer G, Aronson R, et al; AUGUSTUS Investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509-1524. doi: 10.1056/NEJMoa1817083.[PubMed 30883055]

Manning WJ. Management of thromboembolic risk in patients with atrial fibrillation and chronic kidney disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 18, 2018.

Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(6):1308-1313.[PubMed 27299806]

Mavrakanas TA, Samer CF, Nessim SJ, Frisch G, Lipman ML. Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol. 2017;28(7):2241-2248. doi: 10.1681/ASN.2016090980.[PubMed 28302754]

McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2019. doi: 10.1111/jth.14662.[PubMed 31630479]

Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70(2):252-289. doi: 10.1016/j.jacc.2017.03.011.[PubMed 28315732]

Pai M, Douketis JD. Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 13, 2018.

Raskob GE, van Es N, Verhamme P, et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615-624. doi: 10.1056/NEJMoa1711948.[PubMed 29231094]

Raval AN, Cigarroa JE, Chung MK, et al; American Heart Association Clinical Pharmacology Subcommittee of the Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Quality of Care and Outcomes Research. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association [published corrections appear in Circulation. 2017;135(10):e647; Circulation. 2017;135(24):e1144]. Circulation. 2017;135(10):e604-e633. doi:10.1161/CIR.0000000000000477.[PubMed 28167634]

Reed D, Palkimas S, Hockman R, Abraham S, Le T, Maitland H. Safety and effectiveness of apixaban compared to warfarin in dialysis patients. Res Pract Thromb Haemost. 2018;2(2):291–298. doi:10.1002/rth2.12083.[PubMed 30046731]

Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-3241.[PubMed 30165544]

Rottenstreich A, Barkai A, Arad A, Raccah BH, Kalish Y. The effect of bariatric surgery on direct-acting oral anticoagulant drug levels. Thromb Res. 2018;163:190-195. doi: 10.1016/j.thromres.2017.11.006.[PubMed 29157916]

Sarafoff N, Holmes DR. Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 6, 2020.

Schafer JH, Casey AL, Dupre KA, Staubes BA. Safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease. Ann Pharmacother. 2018;52(11):1078–1084. doi:10.1177/1060028018781853.[PubMed 29871510]

Sharifi M, Bay C, Vajo Z, et al. New oral anticoagulants in the treatment of heparin-induced thrombocytopenia. Thromb Res. 2015;135(4):607-609. doi: 10.1016/j.thromres.2015.01.009.[PubMed 25613925]

Shatzel JJ, Crapster-Pregont M, Deloughery TG. Non-vitamin K antagonist oral anticoagulants for heparin-induced thrombocytopenia. A systematic review of 54 reported cases. Thromb Haemost. 2016;116(2):397-400. doi: 10.1160/TH16-02-0101.[PubMed 27075620]

Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States [published correction appears in Circulation. 2018]. Circulation. 2018;138(15):1519-1529. doi: 10.1161/CIRCULATIONAHA.118.035418.[PubMed 29954737]

Stanton BE, Barasch NS, Tellor KB. Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment. Pharmacotherapy. 2017;37(4):412–419. doi:10.1002/phar.1905.[PubMed 28117916]

Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70(24):3042-3067.[PubMed 29203195]

Wang X, Tirucherai G, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56(5):628-636. doi: 10.1002/jcph.628.[PubMed 26331581]

Warkentin TE, Pai M, Linkins LA. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Blood. 2017;130(9):1104-1113. doi: 10.1182/blood-2017-04-778993.[PubMed 28646118]

Xarelto (rivaroxaban) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; January 2019.

Brand Names: International

Apixatrack (EG); Elikvis (UA); Elimbosis (EG); Eliquis (AE, AR, AT, AU, BB, BE, BH, BR, CH, CN, CO, CY, CZ, DE, DK, EE, EG, FR, GB, HK, HR, HU, ID, IE, IL, IS, JP, KR, KW, LB, LT, LU, LV, MT, MY, NL, NO, PH, PL, PT, QA, RO, SA, SE, SG, SI, SK, TH, TR, ZW); Pixcolt (EG)

Last Updated 5/1/20